Hepatocellular carcinoma

Hepatocellular carcinoma is a malignant tumor arising from hepatocytes, the primary functional cells of the liver. While primary liver tumors are relatively uncommon in cats compared to metastatic liver disease, hepatocellular carcinoma represents one of the most frequently diagnosed primary hepatic malignancies in feline patients, second only to bile duct carcinoma. This cancer carries significant clinical importance due to the liver's essential roles in metabolism, protein synthesis, and detoxification, and because of the potential for surgical cure in select cases. Hepatocellular carcinoma typically affects older cats, with most diagnoses occurring in felines over ten years of age, and no specific breed predisposition has been consistently identified.

Hepatocellular carcinoma develops when hepatocytes undergo malignant transformation, leading to uncontrolled cell proliferation and tumor formation within the liver. The tumor can grow in several distinct patterns: as a massive solitary mass confined to one liver lobe, as nodular growths affecting multiple areas of the liver, or as diffuse infiltration throughout the hepatic parenchyma. The massive form, characterized by a single large tumor in one liver lobe, carries the most favorable prognosis because it is often amenable to surgical removal. The nodular and diffuse forms present greater treatment challenges due to their widespread distribution throughout the liver. Understanding the growth pattern is essential for treatment planning and prognosis.

The impact of hepatocellular carcinoma on affected cats depends on tumor size, growth pattern, and the degree to which liver function is compromised. As the tumor grows, it progressively replaces normal liver tissue, potentially leading to liver dysfunction with its wide-ranging metabolic consequences. Large tumors may cause abdominal distension, discomfort, and pressure on adjacent organs. Tumor rupture, though not common, can cause life-threatening internal bleeding. Cats with hepatocellular carcinoma often experience nonspecific symptoms including decreased appetite, weight loss, and lethargy that can be attributed to many conditions, potentially delaying diagnosis. Early detection through regular veterinary care improves the chances of successful treatment.

Treatment options for feline hepatocellular carcinoma offer meaningful hope for extended survival in appropriate cases. Surgical resection provides the best opportunity for long-term control, and the liver's remarkable regenerative capacity allows cats to recover well from removal of affected lobes when the tumor is localized. Complete surgical removal of massive hepatocellular carcinomas can result in prolonged survival times, sometimes measured in years. For tumors that cannot be surgically removed due to their distribution or the cat's condition, management focuses on supportive care and maintaining quality of life. The prognosis varies substantially based on tumor presentation, with solitary resectable tumors having significantly better outcomes than diffuse or metastatic disease.

The precise causes of hepatocellular carcinoma in cats remain incompletely understood, with no single definitive causative agent identified. Unlike human hepatocellular carcinoma, which has well-established associations with chronic hepatitis B and C virus infections and cirrhosis, cats do not harbor comparable hepatitis viruses, and the feline condition appears to develop through different pathways. Current understanding suggests that hepatocellular carcinoma likely arises from accumulated genetic damage to hepatocytes over time, though the specific factors driving this damage in cats have not been fully characterized.

Chronic liver disease and inflammation have been proposed as potential contributing factors to hepatocellular carcinoma development, though the associations are less clear in cats than in humans or dogs. Persistent inflammatory conditions of the liver could theoretically create an environment conducive to malignant transformation through repeated cycles of cellular damage and regeneration. Conditions such as chronic cholangiohepatitis or hepatic lipidosis, if not fully resolved, might contribute to ongoing hepatocyte stress. However, the majority of cats with hepatocellular carcinoma do not have well-documented histories of chronic liver disease, leaving the role of prior inflammation uncertain.

Environmental factors and toxin exposure have been considered as potential contributors to liver cancer development. The liver is the primary organ of detoxification, processing numerous chemicals and potentially carcinogenic substances. Chronic exposure to hepatotoxic substances, including certain drugs, environmental chemicals, or dietary toxins such as aflatoxins from moldy foods, could theoretically contribute to hepatocyte damage and cancer risk. However, specific environmental exposures causally linked to feline hepatocellular carcinoma have not been identified through epidemiological research. The long latency period between potential exposure and cancer development makes establishing these connections challenging.

Age represents the most consistently identified risk factor for hepatocellular carcinoma in cats, with the vast majority of cases occurring in cats over ten years of age. The relationship between aging and cancer development is well established across species and involves the accumulation of genetic mutations over a lifetime, declining immune surveillance against abnormal cells, and changes in DNA repair mechanisms. Older hepatocytes have divided many times and experienced more cumulative exposure to potential mutagens, increasing the likelihood that cancer-promoting mutations will accumulate. This age-related risk underscores the importance of monitoring liver health in senior cats.

The mechanism by which hepatocellular carcinoma develops involves progressive genetic alterations in hepatocytes that enable uncontrolled proliferation, resistance to normal cell death signals, and eventual tumor formation. Early changes may include mutations in genes regulating cell cycle progression, growth factor signaling, and tumor suppression. As mutations accumulate, affected hepatocytes acquire increasingly malignant characteristics. The resulting tumor grows within the liver, potentially compressing or replacing normal liver tissue. Hepatocellular carcinomas have variable metastatic potential, with some remaining localized for extended periods while others spread to regional lymph nodes, lungs, or other organs. Understanding these biological behaviors helps guide treatment decisions and prognostic discussions.

The early warning signs of hepatocellular carcinoma in cats are often subtle, nonspecific, and easily overlooked or attributed to normal aging. Because the liver has substantial functional reserve, significant tumor growth can occur before clinical signs become apparent. Initial symptoms may include slight decreases in appetite, mild weight loss, or subtle changes in activity level that develop gradually over weeks to months. Some cats become slightly more lethargic or spend more time resting. These vague early signs rarely prompt immediate veterinary investigation, contributing to the frequent incidental discovery of liver masses during examinations or imaging for other purposes.

As hepatocellular carcinoma progresses, more definitive symptoms typically develop. Decreased appetite often becomes more pronounced, progressing from mild selectivity about food to more significant anorexia. Weight loss continues and may become visibly apparent, with loss of muscle mass particularly noticeable over the spine and hindquarters. Vomiting and diarrhea may occur, though these are inconsistent findings. Some cats develop increased thirst and urination. General malaise and decreased interaction with family members often develop. The nonspecific nature of these symptoms means they overlap with many other conditions, making thorough diagnostic evaluation essential.

Behavioral changes in cats with hepatocellular carcinoma reflect the systemic effects of cancer and liver dysfunction. Affected cats typically become less active and playful, preferring to rest in quiet locations. Some cats become withdrawn and seek out isolated hiding spots, while others may become uncharacteristically clingy or vocal. Changes in sleep patterns often occur. Grooming behavior may decrease, resulting in a rough or unkempt coat. Some cats show signs of abdominal discomfort, including reluctance to be picked up or touched around the belly. These behavioral changes can be subtle initially but typically progress over time.

Physical signs of hepatocellular carcinoma may include visible or palpable abnormalities along with systemic manifestations. Abdominal enlargement or distension may be noticeable if the tumor is large or if ascites develops. Veterinary palpation may reveal hepatomegaly or discrete masses within the liver region. Jaundice, a yellow discoloration of the skin, gums, and whites of the eyes, may develop if the tumor obstructs bile flow, though jaundice is less common with hepatocellular carcinoma than with bile duct tumors. Pale gums may indicate anemia. Poor body condition and muscle wasting become increasingly apparent as the disease advances.

As hepatocellular carcinoma advances, symptoms intensify and complications may develop. Hepatic encephalopathy, a neurological syndrome resulting from the liver's inability to detoxify blood adequately, may occur in cases with severe liver dysfunction, causing symptoms ranging from subtle behavioral changes to disorientation, head pressing, circling, or seizures. Ascites, the accumulation of fluid in the abdominal cavity, causes visible abdominal distension and may compromise breathing if severe. Coagulation abnormalities from impaired clotting factor production can cause spontaneous bruising or prolonged bleeding. Progressive weakness and debilitation develop as the cancer advances.

Certain symptoms associated with hepatocellular carcinoma constitute medical emergencies requiring immediate veterinary attention. Sudden collapse, extreme weakness, or pale gums may indicate internal bleeding from tumor rupture, a potentially life-threatening complication. Signs of hepatic encephalopathy, including seizures, severe disorientation, or coma, require urgent intervention. Rapid abdominal distension with difficulty breathing suggests significant ascites accumulation needing immediate treatment. Any sudden severe deterioration in a cat with known liver disease warrants emergency evaluation. Owners observing these signs should seek veterinary care immediately rather than waiting to see if improvement occurs.

The diagnostic process for hepatocellular carcinoma may begin when concerning symptoms prompt veterinary evaluation, or the tumor may be discovered incidentally during examination or imaging for other purposes. The veterinarian performs a thorough physical examination, assessing body condition, checking for jaundice, and carefully palpating the abdomen for hepatomegaly or masses. A detailed history establishes any symptoms, their duration and progression, and the cat's overall health status. Initial assessment may suggest liver involvement but cannot distinguish between cancer and other hepatic conditions. The examination findings guide selection of diagnostic tests needed to identify the underlying cause.

Laboratory testing provides important information about liver function and overall health status. Serum biochemistry profiles reveal elevations in liver enzymes, including alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and gamma-glutamyl transferase, reflecting liver damage. Bilirubin levels may be elevated if bile flow is impaired. Albumin and glucose levels help assess liver synthetic function. Coagulation testing evaluates clotting factor production. Complete blood count may reveal anemia or other abnormalities. While blood work cannot definitively diagnose hepatocellular carcinoma, it characterizes the degree of liver dysfunction and helps assess overall health for treatment planning.

Imaging studies are essential for visualizing liver masses and characterizing their extent. Abdominal radiographs may show hepatomegaly or changes in liver shape suggesting a mass, but they have limited sensitivity for detecting early tumors. Abdominal ultrasound provides much more detailed evaluation, allowing visualization of mass lesions within the liver, assessment of whether disease is localized or multifocal, evaluation of other abdominal organs, and identification of any metastatic spread to lymph nodes or other structures. Ultrasound characteristics can suggest tumor type, though definitive differentiation requires tissue sampling. Computed tomography or magnetic resonance imaging may provide additional detail for surgical planning when resection is being considered. Thoracic radiographs check for lung metastases as part of complete staging.

Definitive diagnosis of hepatocellular carcinoma requires cytological or histopathological examination of tumor tissue. Fine-needle aspiration of liver masses can be performed under ultrasound guidance, providing cells for microscopic evaluation. Cytology can often suggest hepatocellular origin but may not reliably distinguish between benign and malignant hepatocyte tumors. Histopathological examination of tissue obtained through percutaneous needle biopsy, surgical biopsy, or complete tumor excision provides the most reliable diagnosis. The pathologist examines tissue architecture and cellular features to confirm the diagnosis and assign a grade reflecting tumor characteristics. Complete staging, incorporating physical examination, blood work, and imaging studies, establishes the extent of disease and guides treatment planning and prognostic discussions.

Treatment planning for hepatocellular carcinoma begins with assessment of tumor distribution and the cat's overall health status. The critical distinction is between massive hepatocellular carcinoma, a solitary tumor confined to one liver lobe, and nodular or diffuse forms with multiple areas of involvement. This distinction largely determines treatment options and prognosis. Cats presenting with concurrent health problems require stabilization before considering definitive treatment. Initial supportive care may include fluid therapy for dehydration, nutritional support, treatment of hepatic encephalopathy if present, and management of any coagulation abnormalities. Once the cat is stable and staging is complete, the veterinary team develops a comprehensive treatment plan.

Surgical resection is the treatment of choice for massive hepatocellular carcinoma and offers the best opportunity for long-term disease control. Liver lobectomy, removing the affected liver lobe along with the tumor, can achieve complete tumor excision when the cancer is confined to one lobe without metastatic spread. The liver's remarkable regenerative capacity allows the remaining lobes to compensate, and most cats recover well from lobectomy procedures. Surgery is performed at specialized centers by experienced surgeons due to the technical demands and risks involved. Complete surgical removal of massive hepatocellular carcinomas has been associated with prolonged survival times, sometimes exceeding one to two years or longer, making this one of the more treatable liver cancers when caught early and appropriately treated.

Medical and palliative management becomes the primary approach for cats with nodular or diffuse hepatocellular carcinoma, metastatic disease, or those who are not surgical candidates due to other health factors. Unfortunately, chemotherapy has not demonstrated significant efficacy against hepatocellular carcinoma in cats, and no standard chemotherapy protocol is recommended. Supportive care focuses on maintaining liver function, managing symptoms, and preserving quality of life. Liver-supportive supplements including S-adenosylmethionine and milk thistle extracts may provide hepatoprotective benefits. Dietary management with appropriate protein levels and energy content supports nutritional status. Fluid therapy at home may be needed for cats with difficulty maintaining hydration.

Supportive care measures play important roles regardless of whether surgery is performed. Nutritional support helps maintain body condition and energy. Highly palatable, easily digestible diets formulated for liver disease provide appropriate nutrition without excessive metabolic demands on compromised liver function. Appetite stimulants may be needed for cats with poor food intake. Managing nausea and vomiting with antiemetic medications improves comfort and enables eating. Ascites management through dietary sodium restriction, diuretics, or periodic therapeutic abdominocentesis provides relief if fluid accumulation is significant. Pain management addresses any discomfort from abdominal masses.

Complementary approaches may be incorporated into the overall care plan based on individual circumstances. While no alternative therapies have proven anti-tumor efficacy, some supportive measures may enhance quality of life. Omega-3 fatty acid supplementation may provide anti-inflammatory benefits. Environmental modifications to reduce stress and ensure easy access to resources support daily functioning. Some owners explore acupuncture or other complementary modalities for supportive care. Close monitoring of the cat's comfort and quality of life allows for ongoing adjustment of the care plan.

Treatment decisions depend on multiple factors unique to each situation. The growth pattern of the tumor, whether massive, nodular, or diffuse, strongly influences options and prognosis. Presence or absence of metastatic disease affects whether aggressive treatment is appropriate. The cat's overall health status and ability to tolerate surgery influences treatment choices. Owner preferences regarding treatment intensity, quality of life priorities, and financial considerations legitimately affect planning. Veterinary specialists can provide detailed information about expected outcomes for different approaches, helping owners make informed decisions aligned with their values while prioritizing their cat's wellbeing.

Recovery following surgical resection of hepatocellular carcinoma requires several days of hospitalization for post-operative monitoring and supportive care. The immediate post-operative period focuses on pain management, maintaining hydration, monitoring for bleeding or other complications, and gradually reintroducing oral feeding. The liver's regenerative capacity begins immediately, with remaining liver tissue expanding to compensate for removed portions. Most cats begin eating within one to three days after surgery, though appetite may be reduced initially. Full recovery from liver lobectomy typically takes several weeks, with gradual improvement in energy, appetite, and activity levels over this time. The surgical incision heals over approximately two weeks.

Post-treatment care extends well beyond initial recovery and involves ongoing monitoring for tumor recurrence and management of overall health. Regular veterinary examinations assess recovery, monitor for complications, and watch for signs of recurrence. Follow-up blood work tracks liver enzyme levels and overall liver function over time. Periodic imaging studies, typically abdominal ultrasound, evaluate the remaining liver and check for tumor regrowth. Liver-supportive medications and supplements may be continued for some time after surgery. Nutritional management remains important, with emphasis on maintaining adequate caloric intake and supporting liver health. Owners play crucial roles in monitoring daily function and reporting any concerning changes.

The prognosis for cats with hepatocellular carcinoma varies substantially based on tumor presentation and treatment received. Cats with massive hepatocellular carcinoma that is completely surgically removed have favorable prognosis, with median survival times reported in some studies as exceeding one to two years. Some cats live significantly longer following successful surgery, enjoying normal quality of life for extended periods. Cats with nodular or diffuse disease have more limited prognosis, typically measured in months with supportive care. Presence of metastatic disease at diagnosis significantly worsens outlook. Individual outcomes vary, and discussions with the veterinary team help establish realistic expectations for each specific situation.

The long-term outlook requires balancing optimism about the potential for extended quality time with realistic understanding of cancer biology. Even with successful surgery, vigilance for recurrence is needed through regular monitoring. Many cats experience meaningful periods of normal quality life following treatment, enjoying their usual activities and routines. The focus throughout long-term management remains on maintaining quality of life and detecting any problems early when intervention might be most effective. Regular reassessment helps ensure that care decisions continue to prioritize the cat's wellbeing. When quality of life cannot be maintained despite best efforts, compassionate end-of-life decisions provide peaceful conclusion to suffering.

True prevention of hepatocellular carcinoma in cats is not currently possible given our incomplete understanding of what causes this cancer to develop. Unlike human hepatocellular carcinoma, where prevention strategies targeting hepatitis viruses and limiting alcohol consumption can reduce risk, no comparable preventable causes have been identified in cats. No specific environmental exposures, dietary factors, or lifestyle modifications have been definitively shown to prevent hepatocellular carcinoma development in feline patients. This reality emphasizes the importance of early detection rather than primary prevention.

Maintaining good overall liver health represents a prudent approach, though its ability to specifically prevent hepatocellular carcinoma is not established. Avoiding exposure to hepatotoxic substances, including certain medications when alternatives exist, minimizes unnecessary liver stress. Preventing obesity reduces the risk of hepatic lipidosis and its associated complications. Prompt treatment of any liver abnormalities identified during routine care prevents progression to chronic disease. Maintaining a healthy indoor environment reduces exposure to potential environmental toxins. While these measures cannot guarantee prevention of liver cancer, they support overall hepatic health.

Dietary considerations support general liver health even if specific cancer prevention effects are not proven. Feeding a complete and balanced commercial diet appropriate for the cat's life stage provides essential nutrients without excess that could stress the liver. Avoiding foods contaminated with mold or toxins removes potential hepatotoxic exposures. Maintaining appropriate body weight prevents obesity-related liver conditions. Ensuring adequate hydration supports all metabolic functions, including hepatic processes. Some owners choose to incorporate liver-supportive supplements into their cat's regimen, though evidence for cancer prevention is lacking.

Regular veterinary care provides the foundation for early detection that can improve outcomes when hepatocellular carcinoma does develop. Annual wellness examinations for adult cats, increasing to twice yearly for seniors, allow veterinarians to detect subtle changes including mild hepatomegaly or liver enzyme elevations that might warrant further investigation. Routine blood work as part of senior wellness screening can reveal liver enzyme abnormalities before symptoms develop. Abdominal palpation during examinations may detect liver enlargement or masses. This proactive approach to health monitoring provides the best opportunity for early cancer detection.

Early intervention when liver abnormalities are detected maximizes treatment options and outcomes. Cats with unexplained liver enzyme elevations benefit from further diagnostic workup including imaging. Masses detected incidentally on ultrasound should be thoroughly characterized rather than simply monitored. Owners of senior cats should be attentive to subtle changes in appetite, weight, or energy that might indicate developing liver problems. Working closely with a veterinarian who knows the individual cat's health history facilitates recognition of abnormal changes. Early detection of hepatocellular carcinoma, particularly the massive form, provides the best opportunity for successful surgical treatment.

Daily management of a cat diagnosed with hepatocellular carcinoma requires attention to nutrition, medication administration, symptom monitoring, and quality of life assessment. Nutritional management is particularly important for cats with liver disease. Feeding a diet appropriate for liver support, whether a prescription liver diet or a carefully selected commercial food, provides essential nutrition without excessive metabolic demands. Small, frequent meals may be better tolerated than large meals. Highly palatable options encourage eating in cats with reduced appetite. Tracking food intake helps identify declining appetite early. Ensuring adequate caloric consumption supports strength and body condition.

Medication management varies depending on individual circumstances and treatment approach. Cats may receive liver-supportive supplements such as S-adenosylmethionine or milk thistle extract products. Antiemetics help control nausea if present. Other medications may be prescribed based on specific symptoms or complications. Establishing a consistent medication routine ensures compliance. Owners should understand the purpose of each medication and watch for potential side effects. Medications requiring refrigeration or specific timing relative to meals need appropriate management. Communication with the veterinary team about any difficulties with medication administration allows for problem-solving.

Maintaining quality of life remains the central focus throughout management of hepatocellular carcinoma. Good quality of life involves the ability to eat comfortably, rest peacefully, engage with family members, and experience pleasure without excessive discomfort or distress. Cats experiencing good quality typically maintain some appetite, respond normally to family interaction, groom appropriately, and rest comfortably. Warning signs of declining quality include persistent nausea, complete loss of appetite, constant discomfort, withdrawal from all interaction, and signs of hepatic encephalopathy. Regular honest assessment using quality of life scales or simple observation helps ensure that management decisions continue to serve the cat's best interests.

Ongoing monitoring for disease progression or complications requires vigilance both at home and through regular veterinary care. Changes in appetite, increasing lethargy, weight loss, or development of jaundice may indicate disease progression. Signs of hepatic encephalopathy such as disorientation, circling, or seizures require immediate attention. Development of ascites with visible abdominal distension should be evaluated. Any sudden deterioration warrants emergency veterinary care. Regular veterinary examinations and periodic blood work and imaging help track disease status objectively. Between visits, owners serve as essential observers with a low threshold for contacting the veterinary team when concerns arise.

Caring for a cat with liver cancer presents emotional challenges for owners alongside practical care demands. The uncertainty of prognosis and the need for ongoing monitoring and decision-making create stress. Watching a beloved companion deal with serious illness is emotionally difficult. Connecting with support resources, including veterinary social workers, support groups, or online communities, provides valuable emotional assistance. Financial planning for ongoing care reduces practical stress. Honest communication with the veterinary team about concerns, hopes, and values ensures that medical decisions align with what matters most. When quality of life can no longer be maintained, preparing emotionally for end-of-life decisions helps owners navigate this final chapter with love and compassion.

Hepatocellular carcinoma in cats does not appear to have a significant breed predisposition based on currently available veterinary literature. Unlike some feline cancers that show clear associations with specific breeds, hepatocellular carcinoma seems to affect cats across all breeds relatively equally when age and other factors are considered. This lack of breed predilection suggests that the factors driving hepatocellular carcinoma development are more closely related to individual exposures, age-related changes, or random genetic events rather than heritable breed-specific characteristics. Both purebred and mixed-breed cats can develop this cancer.

Domestic shorthair and domestic longhair cats represent the majority of diagnosed cases of hepatocellular carcinoma, reflecting their predominance in the general cat population rather than any elevated breed-specific risk. No studies have consistently identified particular purebred breeds with increased or decreased risk for this specific liver cancer. Males and females appear to be affected relatively equally based on available data. The overwhelming demographic characteristic of affected cats is their age, with hepatocellular carcinoma being predominantly a disease of cats over ten years old. Individual health history may be more predictive than breed background.

Given the absence of breed-specific risk factors, screening recommendations for hepatocellular carcinoma focus on age-based approaches applicable to all cats. All senior cats benefit from regular veterinary examinations that include careful abdominal palpation and periodic blood work including liver enzyme panels. Abnormal liver enzymes or hepatomegaly detected during routine care warrant further investigation through imaging studies. Owners of older cats should monitor for signs of liver disease, including decreased appetite, weight loss, vomiting, and changes in behavior. Prompt attention to concerning symptoms provides the best opportunity for early detection. This vigilant approach to liver health in all aging cats is more important than any breed-specific considerations.

Several conditions commonly co-occur with or require differentiation from hepatocellular carcinoma in cats. Other liver tumors, including bile duct carcinoma and metastatic cancer from primary tumors elsewhere, present similarly and require diagnostic evaluation to distinguish. Benign liver masses, including hepatic adenomas, nodular hyperplasia, and cysts, may be detected on imaging and must be differentiated from malignant tumors. Concurrent systemic diseases common in older cats, such as chronic kidney disease, hyperthyroidism, or diabetes, may be present and affect overall management. Inflammatory liver diseases including cholangiohepatitis can occur alongside or be mistaken for neoplastic disease. Comprehensive diagnostic evaluation helps characterize all conditions present.

Several conditions produce symptoms and laboratory findings similar to hepatocellular carcinoma. Cholangiohepatitis, an inflammatory condition of the liver and bile ducts, causes elevated liver enzymes and can cause hepatomegaly overlapping with cancer presentations. Hepatic lipidosis, a potentially serious accumulation of fat in the liver, produces similar biochemical changes. Metastatic cancer from primary tumors in other organs frequently involves the liver and must be distinguished from primary hepatic malignancies. Systemic diseases affecting liver function secondarily, such as right-sided heart failure or severe inflammatory conditions, can cause hepatomegaly and enzyme elevations. Accurate diagnosis through appropriate testing ensures that treatment targets the correct condition.

Complications arising from hepatocellular carcinoma require recognition and management as the disease progresses. Tumor rupture with internal hemorrhage, while not common, represents a life-threatening emergency causing sudden collapse and shock. Hepatic encephalopathy from compromised liver function causes neurological signs ranging from subtle behavior changes to seizures and coma. Ascites accumulation causes abdominal distension and discomfort. Coagulopathy from impaired clotting factor production increases bleeding risk. Metastatic spread to lungs, lymph nodes, or other organs indicates disease progression. Recognizing these complications allows for appropriate intervention or, when quality of life is severely compromised, compassionate end-of-life decisions that prioritize the cat's welfare.